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Implication for health policy/practice/research/medical education:
In the era of COVID-19 pandemic, renal function of the patients–with confirmed COVID-19 infection–needs to be regularly 
monitored during the hospitalization time to intervene as early as possible in order to curb the development of acute renal injuries 
(AKIs). Future epidemiological studies are warranted to determine the cause-effect relationship between COVID-19 and AKI. 
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Introduction
Acute respiratory failure and diffuse alveolar damage are 
common clinical features of coronavirus disease 2019 
(COVID-19) infection in hospitalized patients and can 
lead to multiple organ injuries. So far, there is no definitive 
evidence that COVID-19 infection affects the kidneys 
adversely. However, amongst those who develop severe 
infection and require hospitalization, acute kidney injury 
(AKI) was reported (1). We aim to present the clinical 
outcome associated with AKI in a case with confirmed 
COVID-19 infection. 
Case Presentation
A 32-year-old man was admitted to Ardabil medical 
educational hospital in northwestern Iran on March 14th, 
2020 with a 4-day headache, myalgia, dry cough, shortness 
of breath, and fever ~38°C. He worked in a restaurant as 
a chef and reported that he had not traveled to a foreign 
country in the past 6-month but had contact with his 
co-worker who was coughing few days before the onset 
of his symptoms. The patient was admitted for suspected 
viral pneumonia in the emergency department. On 
admission day, transverse thoracic computed tomography 
(CT) scan showed patchy areas of ground-glass opacities 
with consolidation indicating the possibility of viral 
pneumonia (Figure 1). Appropriate antibiotics and 
hydroxychloroquine started on the admission day. 
Nasopharyngeal and oropharyngeal swabs were taken 
and tested positive for SARS–CoV-2 by real-time reverse-
transcription polymerase chain reaction (rRT-PCR) assay. 
None of the patient’s family members developed COVID-
19-related symptoms, at the time of writing this report. 
Although there is no definitive evidence that coronavirus disease 2019 (COVID-19) affects 
the kidneys adversely, amongst those who develop severe COVID-19 infection and require 
hospitalization, acute kidney injury (AKI) was reported. Here, we report the clinical outcome 
associated with AKI in a 32-year-old man with confirmed COVID-19 infection with no prior 
history of renal malfunction. The AKI was identified during intensive care unit (ICU) course 
with the median creatinine and blood urea nitrogen values of 3.1 mg/dL (normal value: 0.6-1.2 
mg/dL) and 145 mg/dL (normal value:15-45 mg/dL), respectively. Renal function of patients 
hospitalized with COVID-19 infection needs to be monitored regularly to intervene as early 
as possible and to prevent the development of AKI and further kidney complications.
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On day 3, the patient was transferred to the intensive care 
unit (ICU) to receive ventilatory support. On day 7, the 
CT scan was repeated and showed multilobar bilateral 
lung consolidation with ground-glass opacities (Figure 1).
Table 1 shows the laboratory findings on admission day 
and during the ICU course. During the first three days of 
hospitalization, the patient reported no prior history of 
renal malfunction and his routine laboratory test results 
were within normal ranges. However, starting from day 
4, the values of some blood indicators were above the 
normal range including white blood cells, creatinine, 
 
Figure 1. CT images of a 32-year-old patient with SARS-CoV-2. Note: 
Upper panel CT images were taken on day 1 (admission day) and bottom 
panels CT image were taken on day 7 of hospitalization. Left bottom 
panel show extensive ground glass opacities and occasional foci of 
consolidation.
Table 1. Laboratory Data at Hospital Admission and ICU course from day 1 to 16
 Normal range Day 1 Day 4 Day 6 Day 7 Day 8 Day 9 Day 10 Day 11
Day 
12 Day 13
Day 
14 Day 15 Day 16
Creatinine 0.6-1.2 mg/dL 1.1 2.0 4.0 –– 4.0 –– 3.4 –– 3.1 –– 2.7 –– 2.8
Urea 15-45 mg/dL 35 63 61 –– 169 –– 148 –– 145 –– 161 –– 129
Na 132-145 mEq/L 134 136 134 –– 143 –– 138 –– 135 –– 139 –– 141
K 3.5-5.0 mEq/L 4.6 6 4.9 –– 4.3 –– 4.3 –– 4.5 –– 4.7 –– 6.5
WBCs 4000-10000/mcL 23200 31800 –– 12800 –– 15800 –– 18400 –– 16400 –– 18700 13900
Hb 13.5-17.5 g/dL 15.6 14.2 –– 10.7 –– 12.2 –– 12.1 –– 11.0 –– 10.9 8.4
Platelet 
count
150000-
450000/mcL 301000 399000 –– 287000 –– 385000 –– 462000 –– 393000 –– 380000 234000
Lymphocyte 
percent
20-40 percent 7% 6% –– 5% –– 4% –– 7% –– 10% –– 12% 11%
Lymphocyte 
count
1000-4800/
mc/L 1624 1908 –– 640 –– 632 –– 1288 –– 1640 –– 2244 1529
Troponin <0.03 2.2 0.18 –– –– –– –– –– –– –– –– –– –– ––
Abbreviations: Na, sodium; K, potassium; WBCs, white blood cells; Hb, hemoglobin. 
urea, troponin, potassium and neutrophil/lymphocyte 
ratio. According to the kidney disease improving global 
outcomes classification (2), AKI is defined by an increase 
in serum creatinine over baseline (2,3). For this patient, 
AKI was identified during ICU course with the median 
creatinine and blood urea nitrogen values as 3.1 mg/dL 
(normal value:0.6-1.2 mg/dL) and 145 mg/dL (normal 
value:15-45 mg/dL), respectively. 
Once the patient transferred to the ICU, 
hydroxychloroquine was discontinued, and the patient 
was treated with the antiviral agent (i.e., Kaletra), 
meropenem, Targosid, and azithromycin for probable 
secondary bacterial lung infections. All the medications 
were adjusted with glomerular filtration rate during the 
ICU stay and the patient received appropriate intravenous 
fluid management. To manage respiratory failure, the 
patient was supported by mechanical ventilation using 
volume-controlled mode with low tidal volume strategy 
(6 cc/kg), high positive end-expiratory pressure level 
and maintain of plateau pressure below 30 cm H2O. 
Thrombosis prophylaxis with heparin and stress ulcer 
prophylaxis with pantoprazole was administered during 
the hospitalization. At the time of writing this report, the 
patient was transferred from ICU to the hospital ward. 
Discussion
This report describes a critically ill patient who presented 
with laboratory-confirmed COVID-19 associated 
symptoms. The AKI for this patient was identified during 
the ICU course, which was consistent with previous studies 
showing AKI in hospitalized patients with confirmed 
COVID-19 (1) and contradicted another study that 
indicated COVID-19 infection does not result in AKI (4). 
Nevertheless, AKI was recognized as an independent risk 
factor for patients’ in-hospital mortality due to COVID-19 
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(5). Even minor acute variations in kidney function 
can result in short- and long-term dire consequences, 
including chronic kidney disease, end-stage renal disease, 
and decease  (3,6). Evidence shows that microvascular 
dysfunction, inflammation, and metabolic disorders are 
the main mechanisms of AKI (2,7). Therefore, amidst 
the COVID-19 pandemic, which is already taking a toll 
on global health, early diagnosis and identification of 
the underlying etiology are essential to guide proper 
management. Appropriate infectious control, intravenous 
fluid management, and respiratory failure management 
can contribute to preventing further AKIs (2,7-9). 
Conclusion
In sum, renal function of patients hospitalized with 
 COVID-19 infection needs to be monitored regularly 
to intervene as early as possible and to prevent the 
development of AKI. Additional studies are warranted 
to determine the cause-effect relationship between 
COVID-19 and AKI.
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